• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Primary Care
CMECNE

Diagnosis and Management of Primary Hypothyroidism

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Discuss key findings that should alert the clinician to consider a diagnosis of hypothyroidism
2. Describe treatment and medication monitoring for patients with hypothyroid

Estimated time to complete activity: 0.5 hours

Faculty:

Ashley Comfort, MD, FACOG is the Director of Medical Content, ObG Project.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Ashley Comfort, MD, has a financial interest in Pfizer and has no other conflicts of interest to disclose.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from 3/31/2022 through 3/1/2023, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Designated for 0.1 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Read Disclaimer & Fine Print
  • Summary
  • Key Points
    • Definitions
    • Clinical Presentation
    • To Screen or Not to Screen?
    • Diagnosis
    • Pharmacologic Therapy
    • When to Consider Treating Subclinical Hypothyroidism
    • Monitoring Treatment and Endpoints
    • When to Consult an Endocrinologist
    • Other Considerations
  • References

SUMMARY:

Hypothyroidism is a common and easily treatable condition encountered in primary care. The most common cause of hypothyroidism worldwide is iodine deficiency, particularly in developing nations; in the US, it is chronic autoimmune (Hashimoto’s) thyroiditis. Hypothyroidism is 5 to 10 times more common in women and is often associated with other autoimmune disorders (type I diabetes, Addison’s disease, lupus). In many cases it is iatrogenic, caused by radioactive iodine therapy or surgery for hyperthyroidism or thyroid cancer, or drugs such as lithium, amiodarone, interferon alpha, or tyrosine kinase inhibitors. The American Thyroid Association (ATA), in conjunction with the American Association of Clinical Endocrinologists (AACE), offers a useful practice guideline for managing this prevalent endocrine disorder. Of note, the following summary applies to primary hypothyroidism and does not address management of central hypothyroidism or hypothyroidism in pregnancy, which are considered separate topics.

KEY POINTS:

Definitions

  • Overt hypothyroidism
    • High TSH (usually above 10 mU/L)
    • Low free T4
  • Subclinical hypothyroidism
    • TSH above the upper reference range (4.5 to 10 mU/L)
    • Normal free T4

Clinical Presentation 

  • Dry skin
  • Sensitive to cold
  • Fatigue
  • Muscle cramps
  • Voice changes
  • Constipation
  • Weight gain/obesity
  • Thinning hair
  • Impaired Memory
  • Irregular menses
  • Depression
  • Findings associated with severe hypothyroidism
    • Carpal tunnel syndrome | Sleep apnea | Pituitary hyperplasia (causing hyperprolactinemia and associated galactorrhea) | Hyponatremia

To Screen or Not to Screen?

Controversial—Recommendations Vary by Organization

  • ATA: Screen all adults every 5 years beginning at age 35
  • AACE: Screen “older” patients (age not specified)
  • USPSTF does not recommend routine screening
  • However, there is strong evidence to support “case finding” (screening in selected populations)
    • Autoimmune disease | Pernicious anemia | First-degree relative with autoimmune thyroid disease | History of radiation to neck or thyroid surgery | Abnormal thyroid exam | Psychiatric disorder | Taking amiodarone or lithium
  • Other disorders that can be used to support hypothyroid screening include
    • Adrenal insufficiency | Alopecia | Anemia | Cardiac dysrhythmia | Changes in skin texture | Congestive heart failure | Constipation | Dementia | Diabetes mellitus, type 1 | Dysmenorrhea and other menstrual disorders | Hypercholesterolemia | Hypertension | Mixed hyperlipidemia | Malaise and fatigue | Myopathy, unspecified | Prolonged QT interval | Vitiligo | Weight gain

Diagnosis 

Check serum TSH and free T4

  • Multiple clinical scoring systems exist but are not recommended for diagnosis
  • Not necessary or recommended to check T3 (total or free)
  • Mild TSH elevation common in older people and does not necessarily represent subclinical hypothyroidism
  • Do not check TSH in hospitalized patients unless suspicion for primary thyroid process (e.g. myxedema coma)

When to measure Thyroid peroxidase antibody test (TPOAb)

  • Subclinical hypothyroidism | Nodular thyroid | Recurrent miscarriage
    • Patients with subclinical hypothyroidism and TPOAb+ are almost twice as likely to progress to overt hypothyroidism (annual risk 4.3% vs 2.6%)

Pharmacologic Therapy

  • Levothyroxine (Synthroid)
    • Alternative therapies
      • Combination levothyroxine/L-triiodothyronine | Desiccated thyroid hormone
    • ‘Thyroid enhancing’ dietary supplements and nutraceuticals) are NOT recommended or endorsed
  • Starting dose
    • Overt hypothyroidism: 1.6 mg/kg
    • Young, healthy adults: Full replacement dose
    • Patients 50 to 60 years old
      • Without cardiovascular disease: 50 mg
      • With cardiovascular disease: 12.5 to 25 mg, and monitor for development of angina
    • Subclinical hypothyroidism: start with 25 to 75 mg
  • When to take levothyroxine
    • 30 to 60 minutes before breakfast or
    • Bedtime 4 hours after last meal

When to Consider Treating Subclinical Hypothyroidism

  • Symptoms consistent with hypothyroidism
  • TPOAb+
  • Cardiovascular disease/heart failure
  • Improvement in atherosclerotic risk factors (lipids, endothelial function) with treatment

Monitoring Treatment and Endpoints

  • Initially: Check TSH 4 to 8 weeks after initiation or change in dose
  • Once therapeutic dose achieved: Check TSH at 6 months and then yearly thereafter
  • If patient has initiated or stopped a drug that interferes with absorption or metabolism of levothyroxine
    • Check TSH 4 to 8 weeks
    • Examples: Estrogen or androgen | Carbamazepine | Phenobarbital | Phenytoin | Rifampin | Sertraline | Tyrosine kinase inhibitors
  • Avoid overtreatment
    • Happens in 20% of patients treated with levothyroxine
    • Adverse consequences include cardiovascular (angina, atrial fibrillation), skeletal (osteoporosis), psychiatric
  • Therapeutic endpoint: Normalization of TSH

Normalization of a variety of clinical and metabolic endpoints including resting heart rate, serum cholesterol, anxiety level, sleep pattern, and menstrual cycle abnormalities…are further confirmatory findings that patients have been restored to a euthyroid state

  • Therapeutic goal:  TSH 0.45 to 4.12

When to Consult an Endocrinologist

  • Children/infants
  • Difficulty achieving or maintaining euthyroid state
  • Pregnancy or women planning conception
  • Cardiac disease
  • Structural thyroid abnormality (goiter, nodule)
  • Comorbid endocrine disease
  • Unusual constellation of thyroid function test results

Other Considerations

Do Not Use Thyroid Hormone to Treat

  • Symptoms of hypothyroidism without biochemical confirmation (TSH/free T4)
  • Obesity
  • Depression

Adrenal Insufficiency

  • Often associated with concurrent hypothyroidism
  • Treat adrenal insufficiency with steroids first, then reassess thyroid function

Interruptions in Treatment

  • If <6 weeks with no intervening cardiac event or significant weight loss, can resume full dose
  • Preop setting
    • Hypothyroidism affects perioperative outcomes
    • Levothyroxine should be given preoperatively

Patients taking Biotin

  • Hold the supplement for ≥2 days prior to TFT’s especially if taking more than 10 mg

Factors that Alter Thyroxine and Triiodothyronine Binding in Serum

  • Increased T4-binding globulin (TBG)
    • Inherited | Pregnancy| Estrogens| Hepatitis| Porphyria| Heroin| Methadone| Mitotane| 5-FU| SERMS (e.g., tamoxifen, raloxifene)
  • Decreased TBG
    • Inherited| Androgens| Anabolic steroids| Glucocorticoids| Severe Illness| Hepatic failure| Nephrosis| Nicotinic acid| L-Asparaginase
  • Binding inhibitors
    • Salicylates| Furosemide| Free fatty acids| Phenytoin| Carbamazepine| NSAIDs (variable, transient)| Heparin

References:

Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association

Take a post-test and get CME credits

TAKE THE POST TEST

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Primary Care Posts
Next >

Related ObG Topics:

Does Thyroid Hormone Treatment Benefit Patients with Subclinical Hypothyroidism?
ACOG Update: Thyroid Disease in Pregnancy
POSTAL Study Results: Does Levothyroxine Improve Pregnancy Outcomes in Women with Thyroid Autoantibodies Undergoing IVF?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site